MX2019012347A - Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria. - Google Patents

Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.

Info

Publication number
MX2019012347A
MX2019012347A MX2019012347A MX2019012347A MX2019012347A MX 2019012347 A MX2019012347 A MX 2019012347A MX 2019012347 A MX2019012347 A MX 2019012347A MX 2019012347 A MX2019012347 A MX 2019012347A MX 2019012347 A MX2019012347 A MX 2019012347A
Authority
MX
Mexico
Prior art keywords
htcbs
homocystinuria
treatment
kda
optimization
Prior art date
Application number
MX2019012347A
Other languages
English (en)
Inventor
Majtan Tomas
P Kraus Jan
M Bublil Erez
GLAVIN Frank
Sellos-Moura Marcia
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of MX2019012347A publication Critical patent/MX2019012347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un método de PEGilación de una proteína de cistationina ß-sintasa truncada humana que contiene una mutación de una cisteína a una serina en la posición de aminoácido 15 (htCBS C15S). El htCBS C15S se PEGiló con una de las moléculas de PEG de éster de NHS de 5 kDa, 10 kDa o 20 kDa. La supervisión durante el proceso del proceso de PEGilación se usó en el método para reducir los niveles de htCBS C15S sin PEGilar y htCBS C15S con PEGilación insuficiente. La administración de htCBS C15S PEGilado tuvo eficacia a lo largo del tratamiento para la homocistinuria.
MX2019012347A 2017-04-17 2018-04-17 Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria. MX2019012347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762486246P 2017-04-17 2017-04-17
PCT/US2018/027854 WO2018195006A1 (en) 2017-04-17 2018-04-17 Optimization of enzyme replacement therapy for treatment of homocystinuria

Publications (1)

Publication Number Publication Date
MX2019012347A true MX2019012347A (es) 2020-01-15

Family

ID=63856394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012347A MX2019012347A (es) 2017-04-17 2018-04-17 Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.

Country Status (8)

Country Link
US (2) US11324811B2 (es)
EP (1) EP3612214A4 (es)
JP (1) JP7146897B2 (es)
CN (2) CN110753556A (es)
AU (1) AU2018254410A1 (es)
CA (1) CA3059592A1 (es)
MX (1) MX2019012347A (es)
WO (1) WO2018195006A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
SG10201912972SA (en) * 2015-11-09 2020-03-30 Univ Colorado Regents Compositions and methods for treatment of homocystinuria
AU2018254410A1 (en) 2017-04-17 2019-10-10 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
JP2022546550A (ja) * 2019-09-03 2022-11-04 トラヴェール セラピューティクス スウィツァランド ゲーエムベーハー 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法
CN114965761A (zh) * 2022-05-17 2022-08-30 深圳赛保尔生物药业有限公司 聚乙二醇化蛋白药物中n-羟基琥珀酰亚胺的检测方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
JPS57209206A (en) 1981-06-08 1982-12-22 Kanebo Ltd Skin type pack agent
US5656425A (en) 1993-08-17 1997-08-12 Regents Of The University Of Colorado Screening for mutations by expressing cDNA segments
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
EP1221615A2 (en) 1995-04-25 2002-07-10 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
ES2224649T3 (es) * 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
US6174696B1 (en) 1999-11-12 2001-01-16 Genzyme Corporation Method for the determination of homocysteine
AU5781800A (en) 1999-07-06 2001-01-22 General Atomics Methods and compositions for assaying analytes
US20030091543A1 (en) 2001-10-26 2003-05-15 Klein Matthew B. Therapeutic cell preparation grafts and methods of use thereof
WO2003106971A2 (en) 2002-06-17 2003-12-24 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN1552905A (zh) 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070010492A1 (en) 2005-07-11 2007-01-11 Generale Robert J Composition and method for reducing homocysteine caused by drugs containing methyl compounds
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
CN101322840A (zh) 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
JP2011084559A (ja) * 2009-09-16 2011-04-28 Institute Of Physical & Chemical Research 改変融合タンパク質
AU2011212885B2 (en) 2010-02-04 2015-10-01 Aemase, Inc. Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
WO2012001336A1 (en) 2010-07-01 2012-01-05 Isis Innovation Limited Treatment of cognitive disorders
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
WO2015033279A1 (en) 2013-09-04 2015-03-12 Mahesh Kandula Compositions and methods for the treatment of homocystinuria
JP6987741B2 (ja) 2015-07-24 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 生理活性ポリペプチド結合体の製造方法
SG10201912972SA (en) * 2015-11-09 2020-03-30 Univ Colorado Regents Compositions and methods for treatment of homocystinuria
AU2018254410A1 (en) 2017-04-17 2019-10-10 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria

Also Published As

Publication number Publication date
JP2020516322A (ja) 2020-06-11
US11324811B2 (en) 2022-05-10
CA3059592A1 (en) 2018-10-25
AU2018254410A1 (en) 2019-10-10
US20200261555A1 (en) 2020-08-20
JP7146897B2 (ja) 2022-10-04
CN118064414A (zh) 2024-05-24
EP3612214A4 (en) 2021-01-20
EP3612214A1 (en) 2020-02-26
WO2018195006A1 (en) 2018-10-25
US20230039591A1 (en) 2023-02-09
CN110753556A (zh) 2020-02-04

Similar Documents

Publication Publication Date Title
MX2019012347A (es) Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MY191030A (en) Gdf15 fusion proteins and uses thereof
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
MY167804A (en) Treatment of degenerative joint disease
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
MY167232A (en) Polypeptides binding to human complement c5
MX2009007065A (es) Variantes de desintegrina y usos farmaceuticos de los mismos.
MD3347002T2 (ro) Tratamentul bolii Alzheimer într-o populație specifică de pacienți
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
MX2021007434A (es) Peptidos de colageno producidos de forma sintetica y recombinante con eficacia biologica.
MX2019005687A (es) Proteinas klotho recombinantes novedosas y composiciones y metodos que involucran a las mismas.
MD3593808T2 (ro) Polimeri de legare a protonilor pentru administrare orală
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
PH12019550241A1 (en) Mic-1 compounds and uses thereof
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
MX2022005547A (es) Derivados terapeuticos de interleucina-22.
MY173174A (en) Short bio-active peptides for promoting wound healing
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
MX2021015966A (es) Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria.